creat bluematrix
buy voyag phase success lay-up preview
highlight favor risk/reward go earli top line data pt
messag note supplement enhanc previously-publish kit inhibitor deep dive evalu possibl
outcom phase voyag trial recal voyag evalu ayvakit compar stivarga bayri
gastrointestin stromal tumor gist patient trial could potenti enabl registr ayvakit gist patient
previous treat gleevec novn sutent also support pend applic gist
pdufa posit updat proprietari statist power analysi evalu impact rang key paramet
potenti outcom trial base analysi cautiou view voyag potenti success chanc
still think like voyag succe assum po term potenti stock impact think
littl valu current price share gist opportun henc think risk/reward lead data
readout skew upsid estim upon voyag success failur respect maintain buy rate
 modestli reduc pt
top line result phase voyag trial guid earli key upcom binari event
stock recal voyag patient phase trial evalu kit inhibitor ayvakit random current standard-
of-car agent stivarga gist patient progress prior gleevec novn therapi sutent guid
releas top line result earli potenti repres key catalyst stock support potenti snda
file kit gist also supplement compani on-going file kit gist head pdufa date
link could inform trial design potenti kit gist trial biomarker-defin popul recal also ayvakit recent
obtain acceler fda approv treatment patient platelet-deriv growth factor receptor alpha exon mutation-posit
pdgfra gist gist patient nda kit gist gist patient safeti data
includ ayvakit label look rel benign view signific uncertainti still exist fda grant
acceler approv broader kit patient popul given last line set high unmet medic need
within note updat prior statist analysi voyag trial account updat trial enrol
timelin scenario-test key paramet includ variou theoret date databas lock differ
hypothet rate patient censor could potenti affect trial result updat analysi account
acceler enrol last year link complet voyag enrol novemb well guidanc top line result
avail earli scenario-test differ hypothet data cut-off date result rang
estim potenti trial outcom depend ayvakit perform differ rate data censor
base updat analysi cautiou view voyag potenti success chanc still think
like trial succe po base believ like scenario data cutoff late-januari
mid-februari allow month data analysi think voyag could potenti read month mpf
ayvakit arm time think voyag power detect month absolut mpf differ ayvakit
page analyst certif import disclosur
 stivarga indic hypothet mpf month ayvakit minimum may suffici voyag success
compar favor month mpf gener small phase studi
sever risk still exist stivarga could theoret perform better histor grid trial month
would significantli rais efficaci bar ayvakit distribut variou kit mutat voyag given all-com
studi could impact final outcom either ayvakit stivarga ayvakit highli potent pdgfra mutat may
potent exclud kit exon mutat patient small investigator-sponsor studi suggest
stivarga could potent kit exon mutat link stat analysi base sever key assumpt includ
certain trial enrol kinet impact event accrual linear rate event accrual simplifi histor
curv gist time databas lock approach patient censor simplifi
continu believ risk/reward own share skew upsid believ current share price
includ modest contribut kit gist think current share price reflect po voyag
peak share kit gist peak pos-adjust us sale npv attribut pdgfra gist peak
sale advanc system mastocytosi po pos-adjust us sale ret inhibitor pralsetinib
po peak pos-adjust us sale balanc cash bull-cas scenario voyag succe
think upsid potenti per share includ gist even context competitor best-in-class broad-
spectrum kit inhibitor ripretinib given think differ agent sequenc bear-cas scenario voyag
fail think rel limit downsid given believ investor alreadi attribut modest valu ayvakit
kit gist trial failur littl read-through pipelin opportun
also believ modest-to-moder downsid risk neg read-through competitor voyag
succe modest-to-moder upsid voyag unexpectedli fail view current price
justifi attribut opportun kit gist peak us sale base po peak market
share month averag treatment durat balanc cash voyag succe ayvakit expans kit gist
limit ripretinib share post-imatinib sunitinib regorafenib patient share post-ayvakit patient still see
share fairli valu voyag fail ripretinib next-gen kit inhibitor gist see share fairli
valu per share phase intrigu studi gist succe obtain market
share gist share gist
valuat risk
valu blueprint medicin per share use dcf-base valuat method valuat includ
probability-adjust cash flow deriv compani pipelin includ avapritinib use discount rate
termin growth rate appli termin year post-assum gener entri lead pipelin candid
risk valuat includ regulatori commerci setback potenti emerg new
competitor lower product sale expect
page analyst certif import disclosur
valuat risk
price target per share base probability-adjust estim gist net cash balanc
sheet year use discount cash flow analysi use wacc termin growth rate appli
termin year post-assum gener entri
risk rate valuat includ regulatori commerci setback potenti emerg new
competitor lower product sale expect cash flow neg compani may also engag financ activ
dilut exist sharehold
page analyst certif import disclosur
voyag phase success lay-up view
risk/reward favor head earli
page analyst certif import disclosur
bpmc voyag random phase trial ayvakit avapritinib
random vs stivarga regorafenib gist
primari endpoint mrecist
progress imatinib
sunitinib rego-nav
qualiti life
acceler enrol
voyag ye
provid top line result earli
page analyst certif import disclosur
stivarga histor confer month mpf gist
efficaci stivarga gist
specifi
phase grid trial patient strictli
hr vs placebo remain
vs placebo
page analyst certif import disclosur
ayvakit readout highlight month mpf
gist suggest potenti superior stivarga month
ayvakit efficaci across line gist therapi
phase navig data
allow pdgfra gist patient
page analyst certif import disclosur
bpmc updat disclosur around voyag time suggest
top line readout includ potenti event view
linear mpf accrual assum never event
date enrol
event top line readout
expect event line eu trial
state event inform fraction
event primari analysi
linear consist rate enrol
trial site model function recruit trial site
exponenti model exponenti function abx
step function patient enrol
linear rate mpf event accrual mpf month mpf
month respect
total mpf event captur mpf month mpf
month respect
page analyst certif import disclosur
think voyag remain well power detect month mpf
differ power two-tail event
event
event
event
page analyst certif import disclosur
arm arm mavapritinib mavapritinib mregorafenib arm month avapritinib mavapritinib mavapritinib arm arm arm month updat enrol accrual model evalu
potenti impact data cut-off date censor top line readout
potenti mpf readout function ayvakit arm censor data cutoff date
stivarga mpf model month
assum stivarga repeat underperform histor month mpf
phase grid think voyag like succeed
page analyst certif import disclosur
valuat scenario avapritinib gist
page analyst certif import disclosur
see upsid downsid potenti
base potenti phase voyag outcom
po gist
market share
po gist
market share
po gist
valu ex-ret sm pdgfra
guggenheim secur llc analysi estim
includ hypothet scenario po
peak share ayvakit advanc sm well
po peak share pralsetinib ret tumor
page analyst certif import disclosur
